Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform

RNA Biology

Volumn 11, Issue 7, 2014, Pages 845-854

  Liang, Wei Cheng ^a   Wang, Yan ^a   Xiao, Li Jia ^b   Wang, Yu Bing ^a   Fu, Wei Ming ^c   Wang, Wei Mao ^a   Jiang, Hui Qing ^d   Qi, Wei ^d   Wan, David Chi Cheong ^a   Zhang, Jin Fang ^a   Waye, Mary Miu Yee ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Alternative splicing; KLF6; miRNA

Indexed keywords

KRUPPEL LIKE FACTOR 6; MICRORNA; MICRORNA 1301; MICRORNA 210; UNCLASSIFIED DRUG; ISOPROTEIN; KLF6 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; MIRN1301 MICRORNA, HUMAN; MIRN210 MICRORNA, HUMAN; ONCOPROTEIN;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ARTICLE; BIOINFORMATICS; CELL MIGRATION; CELL PROLIFERATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CANCER; LIVER CANCER CELL LINE; LIVER CARCINOGENESIS; LUCIFERASE ASSAY; PROTEIN ANALYSIS; RNA METHYLATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HEPG2 CELL LINE; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; METHYLATION; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HEP G2 CELLS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LIVER NEOPLASMS; METHYLATION; MICRORNAS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS;

EID: 84907551018     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.29356     Document Type: Article

References (60)

1. DiFeo A, Martignetti JA, Narla G. The role of KLF6 and its splice variants in cancer therapy. Drug Resist Updat 2009; 12:1-7; PMID:19097929; http://dx.doi.org/10.1016/j.drup.2008.11.001
2. McConnell BB, Yang VW. Mammalian Krüppel-like factors in health and diseases. Physiol Rev 2010; 90:1337-81; PMID:20959618; http://dx.doi.org/10.1152/physrev.00058.2009
3. Bureau C, Hanoun N, Torrisani J, Vinel JP, Buscail L, Cordelier P. Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis. Curr Genomics 2009; 10:353-60; PMID:20119532; http://dx.doi.org/10.2174/138920209788921010
4. Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS, Odin JA, Diehl JA, Germain D, Friedman SL. Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res 2004; 64:3885-91; PMID:15172998; http://dx.doi.org/10.1158/0008-5472.CAN-03-2818
5. Kimmelman AC, Qiao RF, Narla G, Banno A, Lau N, Bos PD, Nuñez Rodriguez N, Liang BC, Guha A, Martignetti JA, et al. Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene 2004; 23:5077-83; PMID:15064720; http://dx.doi.org/10.1038/sj.onc.1207662
6. Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, Kelley K, Tarocchi M, Friedman SL. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene 2007; 26:4428-34; PMID:17297474; http://dx.doi.org/10.1038/sj.onc.1210223
7. Tarocchi M, Hannivoort R, Hoshida Y, Lee UE, Vetter D, Narla G, Villanueva A, Oren M, Llovet JM, Friedman SL. Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology 2011; 54:522-31; PMID:21563203; http://dx.doi.org/10.1002/hep.24413
8. Botella LM, Sánchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M, Cooreman MP, Ratziu V, Langa C, Vary CP, et al. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 2002; 100:4001-10; PMID:12433697; http://dx.doi.org/10.1182/blood.V100.12.4001
9. Garrido-Martín EM, Blanco FJ, Roquè M, Novensà L, Tarocchi M, Lang UE, Suzuki T, Friedman SL, Botella LM, Bernabéu C. Vascular injury triggers Krüppel-like factor 6 mobilization and cooperation with specificity protein 1 to promote endothelial activation through upregulation of the activin receptor-like kinase 1 gene. Circ Res 2013; 112:113-27; PMID:23048070; http://dx.doi.org/10.1161/CIRCRESAHA.112.275586
10. Li D, Yea S, Li S, Chen Z, Narla G, Banck M, Laborda J, Tan S, Friedman JM, Friedman SL, et al. Krüppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. J Biol Chem 2005; 280:26941-52; PMID:15917248; http://dx.doi.org/10.1074/jbc.M500463200
11. Huang X, Li X, Guo B. KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. J Biol Chem 2008; 283:29795-801; PMID:18755691; http://dx.doi.org/10.1074/jbc.M802515200
12. Ito G, Uchiyama M, Kondo M, Mori S, Usami N, Maeda O, Kawabe T, Hasegawa Y, Shimokata K, Sekido Y. Krüppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res 2004; 64:3838-43; PMID:15172991; http://dx.doi.org/10.1158/0008-5472.CAN-04-0185
13. Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S, Hod E, Harpaz N, Goldberg S, Tal-Kremer S, et al. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 2004; 126:1090-103; PMID:15057748; http://dx.doi.org/10.1053/j.gastro.2004.01.005
14. Jeng YM, Hsu HC. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer 2003; 105:625-9; PMID:12740910; http://dx.doi.org/10.1002/ijc.11123
15. Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, Katz A, Bruix J, Bioulac-Sage P, Martignetti JA, et al. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 2004; 40:1047-52; PMID:15486921; http://dx.doi.org/10.1002/hep.20460
16. Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, Lee JS, Schwartz M, Thung SN, Fiel IM, et al. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol 2007; 46:645-54; PMID:17196295; http://dx.doi.org/10.1016/j.jhep.2006.10.012
17. Camacho-Vanegas O, Narla G, Teixeira MS, DiFeo A, Misra A, Singh G, Chan AM, Friedman SL, Feuerstein BG, Martignetti JA. Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. Int J Cancer 2007; 121:1390-5; PMID:17514651; http://dx.doi.org/10.1002/ijc.22809
18. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, Sato F, Meltzer SJ, Sidransky D. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002; 2:485-95; PMID:12498717; http://dx.doi.org/10.1016/S1535-6108(02)00215-5
19. Hirasawa Y, Arai M, Imazeki F, Tada M, Mikata R, Fukai K, Miyazaki M, Ochiai T, Saisho H, Yokosuka O. Methylation status of genes upregulated by demethylating agent 5-aza-2′-deoxycytidine in hepatocellular carcinoma. Oncology 2006; 71:77-85; PMID:17341888
20. Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, Isaacs WB, Hebbring S, Komiya A, et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 2005; 65:1213-22; PMID:15735005; http://dx.doi.org/10.1158/0008-5472.CAN-04-4249
21. Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Tarocchi M, Akita K, et al. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 2008; 134:1521-31; PMID:18471523; http://dx.doi.org/10.1053/j.gastro.2008.02.015
22. DiFeo A, Feld L, Rodriguez E, Wang C, Beer DG, Martignetti JA, Narla G. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Res 2008; 68:965-70; PMID:18250346; http://dx.doi.org/10.1158/0008-5472.CAN-07-2604
23. Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, et al. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest 2008; 118:2711-21; PMID:18596922; http://dx.doi.org/10.1172/JCI34780
24. Hatami R, Sieuwerts AM, Izadmehr S, Yao Z, Qiao RF, Papa L, Look MP, Smid M, Ohlssen J, Levine AC, et al. KLF6-SV1 drives breast cancer metastasis and is associated with poor survival. Sci Transl Med 2013; 5:69ra12; PMID:23345610; http://dx.doi.org/10.1126/scitranslmed.3004688
25. Muñoz Ú, Puche JE, Hannivoort R, Lang UE, Cohen-Naftaly M, Friedman SL. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1. Mol Cancer Res 2012; 10:1216-27; PMID:22859706; http://dx.doi.org/10.1158/1541-7786.MCR-12-0213
26. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev 2003; 17:419-37; PMID:12600935; http://dx.doi.org/10.1101/gad.1048803
27. Pagani F, Baralle FE. Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet 2004; 5:389-96; PMID:15168696; http://dx.doi.org/10.1038/nrg1327
28. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008; 40:1413-5; PMID:18978789; http://dx.doi.org/10.1038/ng.259
29. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215-33; PMID:19167326; http://dx.doi.org/10.1016/j.cell.2009.01.002
30. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010; 11:252-63; PMID:20216554; http://dx.doi.org/10.1038/nrm2868
31. Qi W, Liang W, Jiang H, Miuyee Waye M. The function of miRNA in hepatic cancer stem cell. Biomed Res Int 2013; 2013:358902; PMID:24383051; http://dx.doi.org/10.1155/2013/358902
32. Huang S, He X. The role of microRNAs in liver cancer progression. Br J Cancer 2011; 104:235-40; PMID:21102580; http://dx.doi.org/10.1038/sj.bjc.6606010
33. Zhang X, Nie Y, Du Y, Cao J, Shen B, Li Y. MicroRNA-181a promotes gastric cancer by negatively regulating tumor suppressor KLF6. Tumour Biol 2012; 33:1589-97; PMID:22581522; http://dx.doi.org/10.1007/s13277-012-0414-3
34. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012; 122:2884-97; PMID:22820290; http://dx.doi.org/10.1172/JCI63455
35. DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, Kalir T, Yao S, Levine A, Birrer MJ, et al. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res 2006; 12:3730-9; PMID:16778100; http://dx.doi.org/10.1158/1078-0432.CCR-06-0054
36. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010; 79:351-79; PMID:20533884; http://dx.doi.org/10.1146/annurev-biochem-060308-103103
37. Huang HY, Chien CH, Jen KH, Huang HD. RegRNA: an integrated web server for identifying regulatory RNA motifs and elements. Nucleic Acids Res 2006; 34:W429-34; PMID:16845041; http://dx.doi.org/10.1093/nar/gkl333
38. Huang X, Le QT, Giaccia AJ. MiR-210 - micromanager of the hypoxia pathway. Trends Mol Med 2010; 16:230-7; PMID:20434954; http://dx.doi.org/10.1016/j.molmed.2010.03.004
39. Rentoft M, Fahlén J, Coates PJ, Laurell G, Sjöström B, Rydén P, Nylander K. miRNA analysis of formalin-fixed squamous cell carcinomas of the tongue is affected by age of the samples. Int J Oncol 2011; 38:61-9; PMID:21109926
40. Zhang Y, He X, Liu Y, Ye Y, Zhang H, He P, Zhang Q, Dong L, Liu Y, Dong J. microRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer. Oncol Rep 2012; 27:685-94; PMID:22134529
41. Fang L, Yang N, Ma J, Fu Y, Yang GS. microRNA-1301-mediated inhibition of tumorigenesis. Oncol Rep 2012; 27:929-34; PMID:22159405
42. Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001; 294:2563-6; PMID:11752579; http://dx.doi.org/10.1126/science.1066326
43. Calderon MR, Verway M, An BS, DiFeo A, Bismar TA, Ann DK, Martignetti JA, Shalom-Barak T, White JH. Ligand-dependent corepressor (LCoR) recruitment by Kruppel-like factor 6 (KLF6) regulates expression of the cyclin-dependent kinase inhibitor CDKN1A gene. J Biol Chem 2012; 287:8662-74; PMID:22277651; http://dx.doi.org/10.1074/jbc.M111.311605
44. Gong M, Yu W, Pei F, You J, Cui X, McNutt MA, Li G, Zheng J. KLF6/Sp1 initiates transcription of the tmsg-1 gene in human prostate carcinoma cells: an exon involved mechanism. J Cell Biochem 2012; 113:329-39; PMID:21928351; http://dx.doi.org/10.1002/jcb.23359
45. Liu J, Du T, Yuan Y, He Y, Tan Z, Liu Z. KLF6 inhibits estrogen receptor-mediated cell growth in breast cancer via a c-Src-mediated pathway. Mol Cell Biochem 2010; 335:29-35; PMID:19707857; http://dx.doi.org/10.1007/s11010-009-0237-8
46. Gehrau RC, D'Astolfo DS, Dumur CI, Bocco JL, Koritschoner NP. Nuclear expression of KLF6 tumor suppressor factor is highly associated with overexpression of ERBB2 oncoprotein in ductal breast carcinomas. PLoS One 2010; 5:e8929; PMID:20126619; http://dx.doi.org/10.1371/journal.pone.0008929
47. Ozdemir F, Koksal M, Ozmen V, Aydin I, Buyru N. Mutations and Krüppel-like factor 6 (KLF6) expression levels in breast cancer. Tumour Biol 2014;In press; PMID:24519062; http://dx.doi.org/10.1007/s13277-014-1678-6
48. Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, Qiao RF, Camacho-Vanegas O, Levine A, Kirschenbaum A, et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res 2005; 65:5761-8; PMID:15994951; http://dx.doi.org/10.1158/0008-5472.CAN-05-0217
49. Hanoun N, Bureau C, Diab T, Gayet O, Dusetti N, Selves J, Vinel JP, Buscail L, Cordelier P, Torrisani J. The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions. J Hepatol 2010; 53:880-8; PMID:20801538; http://dx.doi.org/10.1016/j.jhep.2010.04.038
50. Liu X, Gomez-Pinillos A, Loder C, Carrillo-de Santa Pau E, Qiao R, Unger PD, Kurek R, Oddoux C, Melamed J, Gallagher RE, et al. KLF6 loss of function in human prostate cancer progression is implicated in resistance to androgen deprivation. Am J Pathol 2012; 181:1007-16; PMID:22819534; http://dx.doi.org/10.1016/j.ajpath.2012.06.008
51. Urtasun R, Cubero FJ, Nieto N. Oxidative stress modulates KLF6Full and its splice variants. Alcohol Clin Exp Res 2012; 36:1851-62; PMID:22486562; http://dx.doi.org/10.1111/j.1530-0277.2012.01798.x
52. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007; 6:60; PMID:17894887; http://dx.doi.org/10.1186/1476-4598-6-60
53. Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009; 285:116-26; PMID:19464788; http://dx.doi.org/10.1016/j.canlet.2009.04.031
54. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem 2012; 81:145-66; PMID:22663078; http://dx.doi.org/10.1146/annurev-biochem-051410-092902
55. Duursma AM, Kedde M, Schrier M, le Sage C, Agami R. miR-148 targets human DNMT3b protein coding region. RNA 2008; 14:872-7; PMID:18367714; http://dx.doi.org/10.1261/rna.972008
56. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008; 455:1124-8; PMID:18806776; http://dx.doi.org/10.1038/nature07299
57. Huang S, Wu S, Ding J, Lin J, Wei L, Gu J, He X. MicroRNA-181a modulates gene expression of zinc finger family members by directly targeting their coding regions. Nucleic Acids Res 2010; 38:7211-8; PMID:20591824; http://dx.doi.org/10.1093/nar/gkq564
58. Manni I, Artuso S, Careccia S, Rizzo MG, Baserga R, Piaggio G, Sacchi A. The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J 2009; 23:3957-66; PMID:19608627; http://dx.doi.org/10.1096/fj.09-131847
59. Liang WC, Wang Y, Wan DC, Yeung VS, Waye MM. Characterization of miR-210 in 3T3-L1 adipogenesis. J Cell Biochem 2013; 114:2699-707; PMID:23798503; http://dx.doi.org/10.1002/jcb.24617
60. Zhang JF, He ML, Fu WM, Wang H, Chen LZ, Zhu X, Chen Y, Xie D, Lai P, Chen G, et al. Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling. Hepatology 2011; 54:2137-48; PMID:21809363; http://dx.doi.org/10.1002/hep.24595